Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

ClinicalTrials.gov ID: NCT02836873

Public ClinicalTrials.gov record NCT02836873. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Study identification

NCT ID
NCT02836873
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Theracos
Industry
Enrollment
312 participants

Conditions and interventions

Interventions

  • Bexagliflozin Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
20 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 22, 2016
Primary completion
Jan 10, 2018
Completion
Jan 10, 2018
Last update posted
Jun 29, 2021

2016 – 2018

United States locations

U.S. sites
23
U.S. states
11
U.S. cities
22
Facility City State ZIP Site status
Research Site Fresno California 93720
Research Site La Palma California 90623
Research Site Lincoln California 95648
Research Site Riverside California 92505
Research Site Sacramento California 95825
Research Site San Dimas California 91773
Research Site Monument Colorado 80132
Research Site Norwalk Connecticut 06851
Research Site Hollywood Florida 33024
Research Site Tampa Florida 33607
Research Site West Palm Beach Florida 33401
Research Site Paducah Kentucky 42003
Research Site Auburn Maine 04210
Research Site Rockport Maine 04856
Research Site Nashua New Hampshire 03063
Research Site The Bronx New York 10461
Research Site Stow Ohio 44224
Research Site Oklahoma City Oklahoma 73112
Research Site Austin Texas 78731
Research Site Austin Texas 78758
Research Site North Richland Hills Texas 76180
Research Site Round Rock Texas 78681
Research Site San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02836873, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02836873 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →